IR Biosciences' ImmuneRegen (OTCBB: IRBS) Getting Attention for Its Adult Stem Cell Active Compound
January 26 2010 - 2:54PM
Marketwired
BioMedReports.Com, the news portal which covers Wall Street's
biomedical sector and delivers financial and investment
intelligence to a community of highly informed investors, is
reporting that unlike most newer biotechs of this size and
experience in the market, IR Biosciences' ImmuneRegen (OTCBB: IRBS)
seems to be gathering quite a bit of attention from places like the
NIH, the National Cancer Institute, BARDA (Biomedical Advanced
Research and Development Authority), and the armed forces.
ImmuneRegen's development candidate Homspera® appears to be the
focus of their attention and it happens to be that the compound has
several broad-reaching applications.
Study results have shown its ability to regenerate and
strengthen the immune system and enhance wound healing, thereby
providing possible treatments for acute radiation exposure,
infectious diseases, vaccine adjuvancy, and chemical exposures.
The compound has been modulating the immune system. How it plays
a role for various indications has increased the company's
confidence in its candidacy for various large market opportunities
as well as a rumored and yet to be publicly announced partnership
with one integrated pharmaceutical industry player as they get
further into clinical studies. That same company has a high level
of interest (as do other entities) in purchasing the company's
compound as a therapy for cancer -- melanoma specifically.
A complete report on the company with quotes from its CEO
Michael Wilhelm is available now at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/26267-immuneregen-otcbb-irbs-gaining-attention-for-its-stem-cell-active-compound-.html
Biotech investors interested in accessing the news portal's
complete database of clinical trials and upcoming FDA decisions can
access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com
BioMedReports.Com is a news portal covering the biomedical news
and financial sector. BioMedReports is not paid or compensated to
report news and developments about publicly traded companies.
For more biomedical sector and investment news go to
http://BioMedReports.com
Media Contact: Mary Davila Assistant Editor BioMedReports.Com
e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From May 2024 to Jun 2024
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From Jun 2023 to Jun 2024